Sale

Viral Inactivation Market

Global Viral Inactivation Market Size, Trends, Analysis, Forecast: By Product: Kits and Reagents, Services, Viral Inactivation Systems and Accessories; By Application: Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue and Tissue Products, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Viral Inactivation Market Outlook

The global viral inactivation market size was valued at USD 686.62 million in 2023, driven by rising prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, and rising healthcare expenditures. The market is estimated to grow at a CAGR of 11.5% during the forecast period 2024-2032 to attain a value of USD 1,828.89 million by 2032.

 

Global Viral Inactivation Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America to be a Significant Regional Market for Viral Inactivation

North America is expected to account for a considerable share of the viral inactivation industry. This can be attributed to the robust healthcare infrastructure, and the presence of large pharmaceutical and biopharmaceutical companies. The increasing healthcare research and development (R&D) spending by the United States government is expected to fuel the market in North America. The robust growth of the pharmaceuticals industry, the surging approvals of novel drugs, and the rising penetration of research and academic institutes that promote biotechnology and life science research activities are projected to boost the growth of the viral inactivation industry. Moreover, the increasing use of technologically advanced processes for the production of new and novel drugs is anticipated to bolster the market for viral inactivation in the forecast period.

The viral inactivation industry in Europe is witnessing robust growth due to the increasing spending on research and development (R&D) activities and new product releases in the life sciences industry. Meanwhile, due to the expanding healthcare infrastructure, the Asia Pacific region is predicted to grow rapidly. The increasing prevalence of chronic diseases in developing economies like India and China and the growing interests in life sciences and biotechnology research activities are estimated to invigorate the viral inactivation industry in the coming years.

 

Viral Inactivation: Market Segmentation

Viral inactivation is a method of viral elimination in which the viruses are removed but remain non-infectious in the finished product. The inactivation of viruses is a crucial step in the viral clearance process. Viral inactivation is integral in the manufacturing of biological goods such as tissue and tissue products, stem cell products, vaccines and medicines, among others.

 

Global Viral Inactivation Market By Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By product, the market is divided into:

  • Kits and Reagents
  • Systems
  • Services

The significant applications of viral inactivation are:

  • Vaccines and Therapeutics
  • Stem Cell Products
  • Blood and Blood Products
  • Tissue and Tissue Products
  • Cellular and Gene Therapy

The various end-uses of viral inactivation in the market are:

  • Pharmaceutical and Biotechnology Companies
  • CROs
  • Academic and Research Institutes
  • Others

The EMR report looks into the regional markets of viral inactivation like into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Global Viral Inactivation Market By Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Rising Prevalence of Chronic Diseases to Augment the Market Growth of Viral Inactivation

The rising prevalence of chronic diseases such as cancer, autoimmune disorders, and other diseases, and rising healthcare expenditures are driving the viral inactivation industry. The market is also being propelled by the rapid growth of the pharmaceutical and biotechnology industries, and the increasing launches of novel medication. Various governments are increasingly introducing favourable initiatives to support and fund viral inactivation research activities to prevent viral outbreaks, especially in the wake of the COVID-19 pandemic. With the growing concerns regarding the transmission of blood-borne viruses through plasma-derived medical goods, the demand for effective viral inactivation is significantly surging and driving the market growth.

The increasing investments in research and development (R&D) activities for the development of innovative therapeutics in the life science industry is leading to a surge in the use of kits and reagents, which is invigorating the market growth. Advancements in nano filtration technology are surging the demand for viral inactivation for efficient viral elimination in the manufacturing of biopharmaceutical drugs, therefore adding to the market growth. Furthermore, the increased research and development (R&D) activities for innovations in stem cell and cellular and gene therapy are expected to provide lucrative growth opportunities for the market expansion in the forecast period.

 

Key Industry Players in the Global Viral Inactivation Market

The report gives a detailed analysis of the following key players in the global viral inactivation market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Rad Source Technologies Inc
  • Merck KGaA
  • Parker Hannifin Corp
  • Sartorius AG
  • Cerus Corporation
  • Cytiva (Danaher Corporation)
  • Charles River Laboratories
  • CONVATEC GROUP PLC
  • WuXi AppTec
  • TERUMO BCT, INC.
  • Thermo Fisher Scientific Inc.
  • SCI Automation
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Application
  • End User
  • Region
Breakup by Product
  • Kits and Reagents
  • Services
  • Viral Inactivation Systems and Accessories
Breakup by Application
  • Vaccines and Therapeutics
  • Stem Cell Products
  • Blood and Blood Products
  • Tissue and Tissue Products
  • Cellular and Gene Therapy
Breakup by End-user
  • Pharmaceutical and Biotechnology Companies
  • CROs
  • Academic and Research Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Rad Source Technologies Inc
  • Merck KGaA
  • Parker Hannifin Corp
  • Sartorius AG
  • Cerus Corporation
  • Cytiva (Danaher Corporation)
  • Charles River Laboratories
  • CONVATEC GROUP PLC
  • WuXi AppTec
  • TERUMO BCT, INC.
  • Thermo Fisher Scientific Inc.
  • SCI Automation
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Viral Inactivation Market Overview 

    3.1    Global Viral Inactivation Market Historical Value (2017-2023) 
    3.2    Global Viral Inactivation Market Forecast Value (2024-2032)
4    Global Viral Inactivation Market Landscape
    4.1    Global Viral Inactivation Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Viral Inactivation Product Landscape
        4.2.1    Analysis by Product
        4.2.2    Analysis by Application
        4.2.3    Analysis by End User
5    Global Viral Inactivation Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Viral Inactivation Market Segmentation 
    6.1    Global Viral Inactivation Market by Product
        6.1.1    Market Overview
        6.1.2    Kits and Reagents
        6.1.3    Services
        6.1.4    Viral Inactivation Systems and Accessories
    6.2    Global Viral Inactivation Market by Application
        6.2.1    Market Overview
        6.2.2    Vaccines and Therapeutics
        6.2.3    Stem Cell Products
        6.2.4    Blood and Blood Products
        6.2.5    Tissue and Tissue Products
        6.2.6    Cellular and Gene Therapy
    6.3    Global Viral Inactivation Market by End User
        6.3.1    Market Overview
        6.3.2    Pharmaceutical and Biotechnology Companies
        6.3.3    CROs
        6.3.4    Academic and Research Institutes
        6.3.5    Others
    6.4    Global Viral Inactivation Market by Region
        6.4.1    Market Overview
        6.4.2    North America 
        6.4.3    Europe
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Viral Inactivation Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Viral Inactivation Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Viral Inactivation Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Viral Inactivation Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Viral Inactivation Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Rad Source Technologies Inc
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Merck KGaA
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Parker Hannifin Corp
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Sartorius AG
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Cerus Corporation
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Cytiva (Danaher Corporation) 
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Charles River Laboratories
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    CONVATEC GROUP PLC
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    WuXi AppTec
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    TERUMO BCT, INC.
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Thermo Fisher Scientific Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    SCI Automation
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
18    Global Viral Inactivation Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global market for viral inactivation reached a value of USD 686.62 million in 2023.

The market is anticipated to grow at a CAGR of 11.5% during the forecast period of 2024-2032 to reach a value of USD 1,828.89 million by 2032.

The market is being driven by the increasing approvals of novel drugs, the surging use of technologically advanced processes in development of new drugs, and the robust growth of the healthcare industry.

The growing prevalence of chronic diseases, the rapid growth of the biotechnology and life sciences industry, and advancements in nano filtration technology are projected to propel the growth of the market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major products of viral inactivation are kits and reagents, systems, and services.

The significant applications of viral inactivation in the market are vaccines and therapeutics, stem cell products, blood and blood products, tissue and tissue products, and cellular and gene therapy.

The various end-uses in the market are pharmaceutical and biotechnology companies, CROs, and academic and research institutes, among others.

The major players in the industry are Rad Source Technologies Inc, Merck KGaA, Parker Hannifin Corp, Sartorius AG, Cerus Corporation, Cytiva (Danaher Corporation), Charles River Laboratories, CONVATEC GROUP PLC, WuXi AppTec, TERUMO BCT, INC., Thermo Fisher Scientific Inc., and SCI Automation, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER